Patient data sits at the center of this dementia and brain health question.

Recent patient data confirms what researchers hoped: people are staying on approved Alzheimer’s treatments at meaningful rates, and real-world effectiveness is holding up just as well as clinical trial results promised. A December 2025 readout from the ALZ-NET Registry—tracking over 3,600 patients across 118 clinical sites—showed that patients receiving FDA-approved anti-amyloid therapies maintained adherence sufficient to achieve the safety and effectiveness outcomes demonstrated in controlled trials. This registry data matters because it answers a critical question many families ask: once treatment starts, do people actually stick with it? The answer is increasingly yes, especially as newer formulations make treatment more convenient.

This article explores what the data shows about real-world adherence, why it’s improving, and what newer treatment options mean for patients and caregivers navigating Alzheimer’s management. The shift toward stronger adherence reflects both better medications and smarter delivery methods. When patients can take treatments at home instead of traveling to infusion centers, and when dosing schedules become weekly instead of biweekly, the friction decreases and adherence climbs. This matters for everyone involved—patients avoid burnout, caregivers reduce transportation burden, and clinicians see patients actually benefit from the treatments they prescribe.

What Do Real-World Patient Data Show About Adherence to Alzheimer’s Treatments?
How Have Recent FDA Approvals Made Adherence Easier?
What Percentage of Alzheimer’s Patients Actually Stay on Their Medications?
Which Alzheimer’s Medications Show the Highest Adherence Rates?
What Barriers Still Prevent Patients from Starting or Continuing Alzheimer’s Treatment?
Why Home-Based Administration Changes the Adherence Picture?
What Does Improving Adherence Mean for the Future of Alzheimer’s Care?
Conclusion

What Do Real-World Patient Data Show About Adherence to Alzheimer’s Treatments?

The ALZ-NET Registry provides the most comprehensive real-world evidence available. This registry enrolled over 3,600 patients across 118 clinical sites, creating a dataset far larger than typical clinical trials and reflecting actual practice conditions rather than controlled research settings. The December 2025 data readout is significant because it confirms that real-world patient outcomes match clinical trial safety and effectiveness—a validation that doesn’t always happen when treatments move from research settings to everyday practice. In a subset of 600-plus patients specifically tracked on anti-amyloid therapies, the registry demonstrated strong real-world effectiveness, meaning patients who stayed on the medications saw the cognitive benefits researchers expected.

Why does this matter for the dementia community? Clinical trials typically involve highly motivated participants, careful monitoring, and intensive support. Real-world practice is messier. Patients have complex schedules, transportation challenges, cognitive changes that make medication adherence harder, and caregivers juggling multiple responsibilities. When a large registry shows that adherence rates are sufficient to produce clinical trial-like results, it signals that these medications work when people take them in ordinary life, not just in research settings.

What Do Real-World Patient Data Show About Adherence to Alzheimer's Treatments?

How Have Recent FDA Approvals Made Adherence Easier?

One major breakthrough came in August 2025 when the FDA approved a new weekly subcutaneous maintenance dosing option for lecanemab (Leqembi). Previously, the standard treatment required biweekly intravenous infusions at specialized clinics. For many dementia patients, that meant repeated medical appointments, travel challenges, and the cognitive and emotional burden of regular healthcare interactions. The new weekly subcutaneous option—a self-administered injection that can happen at home—fundamentally changes the adherence equation. Patients no longer need to arrange transportation to infusion centers or sit through two-hour clinic visits every two weeks.

This is not a small distinction. For someone with early Alzheimer’s, repeated clinic visits add up to dozens of hours per year, plus all the logistical planning. For a patient’s caregiver—often an adult child or spouse managing their own work and life—reducing appointment frequency and location burden is genuinely life-changing. Weekly home-based dosing also means patients are more likely to continue treatment consistently, because the barriers that previously caused people to skip doses or discontinue altogether have been reduced. The fact that Eisai submitted supplemental applications for the once-weekly starting dose reflects the industry’s recognition that simplified, home-based regimens drive better real-world outcomes.

What Percentage of Alzheimer’s Patients Actually Stay on Their Medications?

The picture is mixed but trending positive. Current real-world data shows that among patients who initiate treatment for Alzheimer’s disease and related dementias, approximately 74.4% maintain medication adherence when measured by proportion of days covered—meaning they have their medications available and are taking them most of the time. That’s substantially higher than adherence rates for many chronic conditions, suggesting that once patients and caregivers commit to Alzheimer’s treatment, they tend to follow through. However, getting to that point is still a barrier: only about 36% of newly diagnosed patients fill their first prescription within the year following diagnosis, indicating that many people face obstacles—whether financial, logistical, or informational—in accessing treatment in the first place.

Among those who do start treatment, persistence remains challenging for a significant minority. Approximately 44% of patients show non-adherence patterns, meaning they miss doses or have gaps in their medication supply. Within the first year of treatment, about 24% discontinue entirely. These discontinuations happen for various reasons: some patients experience side effects (even though anti-amyloid treatments are generally well-tolerated), others struggle with the logistics of appointments or administration, and some families decide the cognitive or functional changes aren’t proceeding as hoped. Understanding these discontinuation rates is important for families to know—if someone starts an Alzheimer’s treatment and stops, that’s not a personal failure but rather a common pattern that clinicians expect and can address.

What Percentage of Alzheimer's Patients Actually Stay on Their Medications?

Which Alzheimer’s Medications Show the Highest Adherence Rates?

Medication adherence isn’t uniform across all Alzheimer’s drugs. When researchers examined adherence by drug class, they found striking variation. DPP-4 inhibitors—a class of medications sometimes used in dementia management—showed the highest adherence at 66.67%, likely because they’re typically oral daily medications with a straightforward regimen. By contrast, memantine, a common NMDA receptor antagonist used for moderate to severe Alzheimer’s, showed the lowest adherence at 39.13%. Why the difference? Memantine requires careful dose titration—starting low and increasing over weeks—which means patients see multiple dose changes before reaching their maintenance dose.

This complexity, combined with memantine’s administration as separate doses throughout the day, creates more opportunities for patients to forget doses or become confused about their regimen. IV infusions like lecanemab (before the weekly subcutaneous option) fell somewhere in between, easier to remember because of their scheduled clinic visits but harder to access logistically. This variation matters because it shows that medication design and delivery method directly affect whether patients take them consistently. The newer lecanemab formulations deliberately address this by moving to home-based weekly dosing, which should theoretically improve adherence compared to both the previous biweekly infusions and compared to complex oral regimens like memantine. For families choosing among treatment options, knowing that simpler regimens have better adherence histories can inform decisions—especially if a patient’s past history suggests they struggle with complex medication schedules.

What Barriers Still Prevent Patients from Starting or Continuing Alzheimer’s Treatment?

Despite strong real-world effectiveness data and improved formulations, significant gaps remain. The fact that only 36% of newly diagnosed patients fill prescriptions within a year suggests that getting treatment started is the first major barrier. Cost is one obstacle—even with insurance, some patients face substantial copays for newer anti-amyloid therapies. Geographic access is another: not all communities have specialists trained to diagnose early-stage Alzheimer’s or equipped to administer IV infusions or monitor patients on these newer medications.

Some patients and families, understandably, struggle with accepting an Alzheimer’s diagnosis and may delay seeking treatment. Once treatment starts, the 24% annual discontinuation rate tells us that maintaining adherence over months and years presents ongoing challenges. Some discontinuations reflect medical decisions: patients who experience amyloid-related imaging abnormalities (ARIA) on brain imaging, even if asymptomatic, may choose to stop treatment out of concern about future risk. Others discontinue because life circumstances change—a caregiver becomes unavailable, a patient moves to a facility that doesn’t support certain treatments, or financial situations shift. For clinicians and families, this means that starting Alzheimer’s treatment isn’t a one-time decision; it’s an ongoing conversation about whether treatment remains the right choice as circumstances evolve.

What Barriers Still Prevent Patients from Starting or Continuing Alzheimer's Treatment?

Why Home-Based Administration Changes the Adherence Picture?

The shift from clinic-based infusions to home-based injections represents a significant quality-of-life improvement for both patients and caregivers. For someone with mild cognitive impairment or early dementia, the act of preparing for and traveling to repeated medical appointments adds cognitive burden—keeping track of appointments, remembering to arrange transportation, navigating healthcare settings. Weekly subcutaneous dosing at home eliminates this friction. A nurse can come to the patient’s home once weekly, or a caregiver can be trained to administer the injection if appropriate, fitting treatment into the patient’s existing routine rather than disrupting their week around medical visits. This matters psychologically as well.

Many dementia patients struggle with anxiety in unfamiliar settings and around medical procedures. Clinic-based infusions can feel intimidating—sitting in a healthcare environment, having an IV placed, waiting for the infusion to complete. At home, in familiar surroundings with trusted people present, the same treatment feels less burdensome. For caregivers, the reduction in transportation and appointment management can be transformative, especially for those already managing multiple health conditions across a household or balancing caregiving with employment. Early evidence suggests that patients offered home-based formulations show higher adherence than those required to attend clinic appointments, a pattern the FDA’s approval of weekly subcutaneous lecanemab deliberately leverages.

What Does Improving Adherence Mean for the Future of Alzheimer’s Care?

The trend toward higher adherence and easier-to-use formulations signals a fundamental shift in how Alzheimer’s disease will be managed over the next decade. As anti-amyloid therapies continue to improve and more formulations become available in home-based or simplified delivery forms, the barrier for treatment will progressively lower. Patients diagnosed earlier in their disease course—when cognitive changes are subtle and mild—will have more options for convenient, accessible treatment. The continued expansion of real-world registry data like ALZ-NET will help clinicians understand which patients benefit most from which treatments, allowing for more personalized medicine. However, significant work remains.

Ensuring that newly diagnosed patients have access to early diagnosis and treatment requires expanding specialist capacity and improving primary care providers’ skills in cognitive assessment. Making sure that newer formulations are affordable and available to patients across all socioeconomic backgrounds remains a policy challenge. And supporting patients and families through years of consistent, appropriate treatment—understanding when to continue, when to adjust, when to pause—will remain central to good dementia care. The data showing strong real-world adherence is encouraging, but it represents only the patients who succeeded in starting and staying on treatment. The next phase of progress involves making that success the norm, not the exception.

Conclusion

Patient data from the ALZ-NET Registry and real-world medication adherence studies confirms that people receiving approved Alzheimer’s treatments—particularly newer anti-amyloid therapies—maintain adherence at rates sufficient to produce clinical trial-level effectiveness in ordinary practice settings. A weighted-average adherence rate of 74.4% among patients on treatment, combined with strong safety data from 3,600+ patients across clinical sites, demonstrates that these medications work when people take them consistently. The introduction of home-based weekly subcutaneous dosing for lecanemab represents a major step forward, removing many of the logistical barriers that previously caused people to skip doses or discontinue treatment.

For patients and families navigating an Alzheimer’s diagnosis, this data offers both encouragement and practical guidance. Encouragement comes from knowing that treatment works in real-world conditions, not just research settings, and that newer formulations make treatment more convenient than ever before. Practical guidance comes from understanding that some medications have better adherence profiles than others, and from recognizing that starting treatment and maintaining it over time are distinct challenges. If you’re considering Alzheimer’s treatment or supporting someone in that decision, discussing the latest data—and which formulations best fit your situation—with a dementia specialist can help optimize both access and long-term adherence.